Amgros is a stakeholder with the 5 regions as stakeholders. With a view to providing stakeholders' hospital pharmacies with medicinal products and the resale of individual stakeholders to the Faroe Islands and Greenland, Amgros I/S wishes to conclude framework agreements for the medicinal products listed in Title II.2.4. The framework agreements are non-exclusive. Amgros I/S resells the medicines to the hospital pharmacies at Amgros I/S's purchase price with a supplement. Framework agreements are concluded without purchasing obligation and hospital pharmacies in the regions are not obliged to use Amgros' framework agreements.
The tender number includes the following medicines:
Tender No: 1,
ATC Code: M05BX07,
Generic Name: Vosoritid,
Dispensing form: Injection liquid,
Strength: 0.4 mg,
Unit value: 0,7 mg,
Volume in units: 9 999.
Tender No: 1,
ATC Code: M05BX07,
Generic Name: Vosoritid,
Dispensing form: Injection liquid,
Strength: 0.56 mg,
Unit value: 0,7 mg,
Volume in units: 9 999.
Tender No: 1,
ATC Code: M05BX07,
Generic Name: Vosoritid,
Dispensing form: Injection liquid,
Strength: 1.2 mg,
Unit value: 0,7 mg,
Volume in units: 9 999.
Each tender number shall be considered a stand-alone subcontract and shall be offered independently of the other tender numbers. Thus, a vendor may choose to offer at one, more or all tender numbers, and allocation is made separately for each offer number. Please refer to the tender conditions, including the submission of tenders under the individual tender numbers.
Under the designation “quantity in units” above is indicated an estimated consumption of the drugs under the supply number, but the real consumption may differ significantly from there. This needs suppliers to factor in. The background to this is that these are medicines for patient care in public hospitals where the needs of the patient must be met. The medicinal products offered are also covered by one or more treatment instructions provided by the Board of Medicine and the consumption of the various medicines may be significantly affected by it. For a detailed description, refer to the terms of tender and the framework agreement.
The total value estimated in paragraph II.1.5 above is equal to the maximum value of the lot.
The maximum value of the partial agreement shall be increased by 50% for each new indication the medicinal product on the sub-agreement may be obtained in the period from the publication of the tender notice until the expiry of the subcontract.